Nicoletta Loggia
Hoofd Techniek/Wetenschap/O&O bij ORCHARD THERAPEUTICS PLC
Actieve functies van Nicoletta Loggia
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Hoofd Techniek/Wetenschap/O&O | 09-09-2021 | - |
| CANDEL THERAPEUTICS, INC. | Directeur/Bestuurslid | 07-06-2023 | - |
| Independent Dir/Board Member | 07-06-2023 | - |
Loopbaan van Nicoletta Loggia
Opleiding van Nicoletta Loggia
| University of Pavia | Doctorate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 2 |
| Italië | 2 |
| Verenigde Staten | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Nicoletta Loggia
- Ervaring
